AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Cyclopharm secures US patent extension for Technegas to 2031
- Strengthens exclusivity in world’s largest healthcare market
- Bolsters commercialisation pathway in lung imaging space
Cyclopharm (ASX:CYC) has achieved a critical milestone in its US commercialisation plans with the United States Patent and Trademark Office (USPTO) granting a maximum five-year extension on its Technegas patent. The updated coverage now ensures patent protection until 2031, delivering extended market exclusivity in one of the world’s most lucrative healthcare markets.
Strategic Win in Nuclear Medicine
Technegas is a nuclear medicine ventilation imaging agent designed to simulate gas behavior in the lungs, enabling superior imaging of lung peripheries. This unique capability enhances diagnostic precision for conditions such as pulmonary embolism and other emerging respiratory indications.
The patent extension follows a comprehensive evaluation by both the USPTO and the US Food and Drug Administration (FDA), underscoring the clinical relevance and innovation behind the technology. Cyclopharm has been steadily advancing its US regulatory journey and this approval adds further momentum to its commercial push in North America.
Strong Foundation for US Market Expansion
The new patent term allows uninterrupted exclusivity, shielding Cyclopharm from potential competition in the short to medium term. With regulatory barriers now lowered and market exclusivity guaranteed, the company is well-positioned to tap into the significant revenue potential that the US healthcare system offers.
This development complements Cyclopharm’s ongoing investments in next-generation innovations, intellectual property protection, and commercial infrastructure, including an expanded team for US business development.
Potential Catalyst Among ASX Dividend Stocks
While Cyclopharm is primarily known for its healthcare innovation, its recent momentum may attract attention among ASX dividend stocks, especially as investors seek growth and defensiveness in evolving market conditions.
The move also strengthens the company's standing in the broader S&P/ASX200 narrative, as innovation-led healthcare companies become increasingly pivotal to the index’s diversification and long-term performance.
Forward-Looking Prospects
Cyclopharm is not only focused on maximising its US opportunity but also pursuing broader global initiatives to extend the utility and protection of its Technegas platform. From new patent filings to advancing complementary technologies, the company aims to fortify its position as a leader in functional lung imaging.
With exclusivity secured and regulatory hurdles cleared, Cyclopharm’s path forward appears increasingly robust in a market ripe for advanced diagnostic tools. The Technegas platform, supported by this new patent win, is poised to play a central role in the evolution of nuclear medicine diagnostics across key geographies.
